Marek Śmiłowski

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 668 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +4

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

James F. Howard, Saskia Bresch, Angela Genge et al. · The Lancet Neurology · 2023 · 250 citations

Medicine, Pharmacotherapy, Pain Management +2

Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study

Carlo Antozzi, Tuan Vu, Sindhu Ramchandren et al. · The Lancet Neurology · 2025 · 76 citations

Medicine, Pharmacology, Pharmacotherapy +5

Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)

James F. Howard, Tuan Vu, George Li et al. · Neurotherapeutics · 2024 · 47 citations · Full text

Medicine, Endocrinology, Internal Medicine +6

Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study

James F. Howard, Saskia Bresch, Constantine Farmakidis et al. · Therapeutic Advances in Neurological Disorders · 2024 · 35 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13